Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity

Chemotherapeutic treatment of breast cancer is based on maximum tolerated dose (MTD) approach. However, advanced stage tumors are not effectively eradicated by MTD owing to suboptimal drug targeting, onset of therapeutic resistance and neoangiogenesis. In contrast, “metronomic” chemotherapy is based...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzucchelli, Serena, Bellini, Michela, Fiandra, Luisa, Truffi, Marta, Rizzuto, Maria A., Sorrentino, Luca, Longhi, Erika, Nebuloni, Manuela, Prosperi, Davide, Corsi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352408/
https://www.ncbi.nlm.nih.gov/pubmed/28039473
http://dx.doi.org/10.18632/oncotarget.14204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352408/
https://www.ncbi.nlm.nih.gov/pubmed/28039473
http://dx.doi.org/10.18632/oncotarget.14204

Ejemplares similares